Search: WFRF:(Algaba Ferran) >
Sequential Intraves...
Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder : Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
-
Oosterlinck, Willem (author)
-
Kirkali, Ziya (author)
-
Sylvester, Richard (author)
-
show more...
-
da Silva, Fernando Calais (author)
-
- Busch, Christer (author)
- Uppsala universitet,Molekylär och morfologisk patologi,Alafuzoff
-
Algaba, Ferran (author)
-
Collette, Sandra (author)
-
Bono, Aldo (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2011
- 2011
- English.
-
In: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 59:3, s. 438-446
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Bacillus Calmette-Guerin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS). Objective: Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS. Design, setting, and participants: In a noncomparative phase 2 study, 96 patients with primary/secondary/concurrent CIS of the urinary bladder were randomized to sequential MMC plus BCG or to BCG alone after TUR. Intervention: Patients received six weekly instillations of MMC followed by six weekly instillations of BCG or six weekly instillations of BCG, 3 wk rest, and three further weekly instillations of BCG. Complete responders received three weekly maintenance instillations at 6, 12, 18, 24, 30, and 36 mo in accordance with the initial randomization. Measurements: End points were complete response (CR) rate at the first control cystoscopy 16-18 wk after start of treatment, disease-free interval, overall survival, and side effects. Results and limitations: Ninety-six patients were randomized, 48 to each treatment group. Ten patients were ineligible, and three did not start treatment. In all random-ized patients, CR rates on MMC plus BCG and BCG alone were 70.8% and 66.7%, respectively. In 83 eligible patients who started treatment, CR rates were 75.6% and 73.8%, respectively. Based on a median follow-up of 4.7 yr, 25 patients (52.1%) on MMC plus BCG and 22 patients (45.8%) on BCG alone were disease free. Twelve patients stopped treatment due to toxicity: three during induction (two MMC plus BCG, one BCG) and nine during maintenance (three MMC plus BCG, six BCG). Conclusions: In the treatment of patients with CIS, sequential chemoimmunotherapy with MMC plus BCG had acceptable toxicity. CR and disease-free rates were similar to those on BCG alone and to previous publications on sequential chemoimmunotherapy.
Keyword
- Bacillus Calmette-Guerin
- Carcinoma in situ
- Intravesical therapy
- Mitomycin C
- Non-muscle-invasive bladder cancer
- Randomized clinical trial
- Urinary bladder
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database